发布求助

文献互助智能选刊最新文献

Clinical pharmacy最新文献

筛选

英文中文

Pathophysiology of septic shock and implications for therapy. 脓毒性休克的病理生理学及其治疗意义。

Clinical pharmacy Pub Date : 1993-11-01 DOI: 10.1093/ajhp/51.2.241a

Barron Rl

{"title":"Pathophysiology of septic shock and implications for therapy.","authors":"Barron Rl","doi":"10.1093/ajhp/51.2.241a","DOIUrl":"https://doi.org/10.1093/ajhp/51.2.241a","url":null,"abstract":": Current knowledge about the pathophysiology of septic shock is reviewed, and biotechnology-based therapies under development are discussed. Patients with septic shock begin their clinical course with leukocytosis, fever, tachycardia, tachypnea, and organ hypoperfusion; shock ensues as immunologic and vasoactive mediators produce hypotension. There are many metabolic and cardiovascular responses, and single- or multiple-organ failure is common. Patients may experience adult respiratory distress syndrome. A multitude of endogenous and exogenous factors have been linked to the pathophysiology of sepsis and septic shock, including (1) endotoxin from gram-negative bacteria, (2) peptidoglycan and exotoxins from gram-negative bacteria, (3) endotoxin-binding proteins and receptors, (4) bactericidal proteases, (5) exotoxins from gram-positive bacteria, (6) acute-phase proteins and proteases, (7) cytokines, (8) arachidonic acid metabolites, (9) complement, (10) beta-endorphin, (11) histamine, (12) stimulation of intrinsic and extrinsic coagulation pathways and proteases, and (13) endothelium-derived factors and adhesion molecules. Molecular entities and strategies under development to combat septic shock include monoclonal antibodies to endotoxin, active immunization with lipid-A analogues, bactericidal permeability-increasing protein, interleukin inhibitors, and inhibitors of tumor necrosis factor-alpha. Successful treatment of septic shock will probably require a combination of agents, including antimicrobials. An ideal goal for biotechnology in the area of septic shock is to prevent invading pathogens from overstimulating the host's immune system and to systematically eliminate those pathogens. Biotechnology is opening new avenues to the treatment of septic shock.","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"34 1","pages":"829-845"},"PeriodicalIF":0.0,"publicationDate":"1993-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74309801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 34

Prophylaxis with aztreonam plus metronidazole during appendectomy. 在阑尾切除术中应用氨曲南加甲硝唑预防。

Clinical pharmacy Pub Date : 1993-11-01

L H Danziger

引用次数: 0

Pathophysiology of septic shock and implications for therapy. 脓毒性休克的病理生理学及其治疗意义。

Clinical pharmacy Pub Date : 1993-11-01

R L Barron

{"title":"Pathophysiology of septic shock and implications for therapy.","authors":"R L Barron","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Current knowledge about the pathophysiology of septic shock is reviewed, and biotechnology-based therapies under development are discussed. Patients with septic shock begin their clinical course with leukocytosis, fever, tachycardia, tachypnea, and organ hypoperfusion; shock ensues as immunologic and vasoactive mediators produce hypotension. There are many metabolic and cardiovascular responses, and single- or multiple-organ failure is common. Patients may experience adult respiratory distress syndrome. A multitude of endogenous and exogenous factors have been linked to the pathophysiology of sepsis and septic shock, including (1) endotoxin from gram-negative bacteria, (2) peptidoglycan and exotoxins from gram-negative bacteria, (3) endotoxin-binding proteins and receptors, (4) bactericidal proteases, (5) exotoxins from gram-positive bacteria, (6) acute-phase proteins and proteases, (7) cytokines, (8) arachidonic acid metabolites, (9) complement, (10) beta-endorphin, (11) histamine, (12) stimulation of intrinsic and extrinsic coagulation pathways and proteases, and (13) endothelium-derived factors and adhesion molecules. Molecular entities and strategies under development to combat septic shock include monoclonal antibodies to endotoxin, active immunization with lipid-A analogues, bactericidal permeability-increasing protein, interleukin inhibitors, and inhibitors of tumor necrosis factor-alpha. Successful treatment of septic shock will probably require a combination of agents, including antimicrobials. An ideal goal for biotechnology in the area of septic shock is to prevent invading pathogens from overstimulating the host's immune system and to systematically eliminate those pathogens. Biotechnology is opening new avenues to the treatment of septic shock.</p>","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"12 11","pages":"829-45"},"PeriodicalIF":0.0,"publicationDate":"1993-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19152468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bezoar formed by fragments of extended-release nifedipine tablets. 硝苯地平缓释片碎片形成的牛黄。

Clinical pharmacy Pub Date : 1993-11-01

M F Shepherd

引用次数: 0

Three categories of nonprescription drug products to carry new warnings. 三种非处方药产品将有新的警告。

Clinical pharmacy Pub Date : 1993-11-01

引用次数: 0

Ketoconazole and gastric acidity. 酮康唑与胃酸。

Clinical pharmacy Pub Date : 1993-11-01

M Goemann, T G Cantú

引用次数: 0

Criteria for long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) in adult inpatients and outpatients. 成人住院和门诊患者长期使用非甾体抗炎药(NSAIDs)的标准

Clinical pharmacy Pub Date : 1993-10-01

C B Good, B M Hruska, T Wheeler

引用次数: 0

Pharmacokinetics of mexiletine in middle-aged and elderly patients. 美西汀在中老年患者的药代动力学。

Clinical pharmacy Pub Date : 1993-10-01

K Ueno, Y Kawaguchi, K Tanaka

引用次数: 0

Assay for midazolam in liquor folliculi during in vitro fertilization under anesthesia. 麻醉下体外受精卵泡液中咪达唑仑的测定。

Clinical pharmacy Pub Date : 1993-10-01

J Chopineau, J E Bazin, M P Terrisse, V Sautou, L Janny, P Schoeffler, P Bastide

引用次数: 0

New FDA policy encourages inclusion of women in clinical trials. FDA新政策鼓励女性参与临床试验。

Clinical pharmacy Pub Date : 1993-10-01

引用次数: 0

首页上一页

8
9
...
10

下一页尾页

联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1

京公网安备 11010802042870号

Book学术文献互助

Book学术文献互助群
群号：481959085

Book学术官方微信